PT  - JOURNAL ARTICLE
AU  - Barnard, Rosanna C.
AU  - Davies, Nicholas G.
AU  - ,
AU  - Jit, Mark
AU  - Edmunds, W. John
TI  - Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era
AID  - 10.1101/2021.11.22.21266584
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.11.22.21266584
4099  - http://medrxiv.org/content/early/2022/05/20/2021.11.22.21266584.short
4100  - http://medrxiv.org/content/early/2022/05/20/2021.11.22.21266584.full
AB  - England has experienced a heavy burden of COVID-19, with multiple waves of SARS-CoV-2 transmission since early 2020 and high infection levels following the emergence and spread of Omicron variants since late 2021. In response to rising Omicron cases, booster vaccinations were accelerated and offered to all adults in England. Using a model fitted to more than 2 years of epidemiological data, we project potential dynamics of SARS-CoV-2 infections, hospital admissions and deaths in England to December 2022. We consider key uncertainties including future behavioural change and waning immunity, and assess the effectiveness of booster vaccinations in mitigating SARS-CoV-2 disease burden between October 2021 and December 2022. If no new variants emerge, SARS-CoV-2 transmission is expected to decline, with low levels remaining in the coming months. The extent to which projected SARS-CoV-2 transmission resurges later in 2022 depends largely on assumptions around waning immunity and to some extent, behaviour and seasonality.Competing Interest StatementRCB, NGD, MJ and WJE are participants of the UK's Scientific Pandemic Influenza Group on Modelling. WJE attends the UK's Scientific Advisory Group for Emergencies. All authors declare no competing interests.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (Grant agreement number 101003688: RCB, MJ, WJE). This work reflects only the authors' view. The European Commission is not responsible for any use that may be made of the information it contains. This project has also received funding from the UK Medical Research Council (MC_PC_19065: NGD, WJE), was partly funded by the National Institute for Health Research (NIHR) (Health Protection Research Unit for Immunisation NIHR200929: NGD, MJ; Health Protection Research Unit in Modelling and Health Economics NIHR200908: MJ, WJE; PR-OD-1017-20002: WJE). Funding statements for CMMID COVID-19 working group members are listed in the Supplementary material.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this research was given by the London School of Hygiene & Tropical Medicine Ethics Committee, project ID: 22828.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis code and data will be made available upon publication at: https://github.com/rosannaclairebarnard/newcovid3 https://github.com/rosannaclairebarnard/newcovid3